Standout Papers

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-... 2022 2026 2023 2024145
  1. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 (2022)
    Solange Peters, Arnaud Scherpereel et al. Annals of Oncology

Immediate Impact

2 by Nobel laureates 1 from Science/Nature 58 standout
Sub-graph 1 of 22

Citing Papers

Metalloradical Catalysis: General Approach for Controlling Reactivity and Selectivity of Homolytic Radical Reactions
2024 Standout
ALKBH5-mediated m6A modification of IL-11 drives macrophage-to-myofibroblast transition and pathological cardiac fibrosis in mice
2024 Standout
2 intermediate papers

Works of Thomas Spires being referenced

Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection Fraction
2020
[2.2.1]-Bicyclic sultams as potent androgen receptor antagonists
2016

Author Peers

Author Last Decade Papers Cites
Thomas Spires 256 175 76 214 15 749
Fladia Phoenix 217 79 161 110 25 873
Keiichi Yoshimoto 85 118 60 247 14 850
P.J. Wyld 157 185 25 183 19 876
Cristina Bozzola 130 85 132 149 22 947
Michael Klimas 226 142 27 157 24 907
Jessie Gu 181 176 90 59 17 700
Jimmy D. Page 70 150 33 172 20 965
Xiaoqian Qian 270 181 41 202 12 857
Yu-Juei Hsu 183 73 51 221 19 823
Virginia C. Canale 114 104 20 186 20 836

All Works

Loading papers...

Rankless by CCL
2026